Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04732910

Modulate-CF: Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators

This observational study evaluates the effect of therapy with cystic fibrosis transmembrane regulator (CFTR) modulators on CFTR function measured by the CFTR biomarker intestinal current measurement (ICM), nasal potential difference (NPD) and sweat chloride in a post-approval setting in patients with cystic fibrosis (CF).

Recruiting

Interested in participating?

Request Info

Key information

Age range

6 month and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Charité - Universitätsmedizin Berlin, Berlin, State of Berlin, Germany

Loading trial locations.

About this study

Cystic fibrosis transmembrane regulator (CFTR) biomarker (intestinal current measurement (ICM), nasal potential difference (NPD), sweat chloride) before the start of therapy and 12 and 52 weeks after initiation of therapy Clinical parameters (anthropometry, lung function, lung magnetic resonance imaging (MRI), lung computer tomography (CT)) before the start of therapy and after initiation of therapy Assessment of airway secretion specimens before the start of therapy and after initiation of therapy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Decision for cystic fibrosis (CF) transmembrane regulator (CFTR)-modulator therapy by the patient and the caring CF physician
  • Signed informed consent form (ICF) and, where appropriate, signed assent form.

Exclusion criteria

  • Ongoing participation in an investigational drug study (including studies investigating lumacaftor, tezacaftor or ivacaftor)

Treatment and study plan

Treatment with cystic fibrosis transmembrane regulator (CFTR) modualtors Ivacaftor, Lumacaftor-Ivacaftor, Tezacaftor-Ivacaftor, Elexacaftor-Tezacaftor-Ivacaftor, Vanzacaftor-Tezacaftor-Deutivacaftor

Drug

observational

Primary outcomes

  1. Intestinal current measurement (ICM)

    Time frame: 12 weeks

    Absolute change from baseline of the chloride secretory ion current induced by cyclic adenosine monophosphate (cAMP) stimulation (forskolin/3-isobutyl-1-methylxanthine (IBMX)) in rectal tissue determined by intestinal current measurement (ICM) as a cystic fibrosis transmembrane conductance regulator (CFTR) biomarker

Secondary outcomes

  1. Forced expiratory volume in 1 second (FEV1)

    Time frame: quaterly in the first year, yearly thereafter up to 5 years

    Absolute change from baseline in percent predicted forced expiratory volume in 1 second (FEV1) in spirometry

  2. Nasal potential Difference (NPD)

    Time frame: 12 weeks

    Absolute change from baseline total chloride response (zero chloride and isoproterenol) in nasal potential Difference (NPD) as a cystic fibrosis transmembrane conductance regulator (CFTR) biomarker

  3. Sweat chloride

    Time frame: 12, 52 weeks, yearly thereafter up to 5 years

    Absolute change from baseline of the chloride concentration in Gibson-Cooke pilocarpine iontophoresis sweat test as a cystic fibrosis transmembrane conductance regulator (CFTR) biomarker

  4. Lung clearance index (LCI)

    Time frame: quaterly in the first year, yearly thereafter up to 5 years

    Absolute change from baseline of the lung clearance index (LCI)

  5. Lung magnetic resonance imaging (MRI)

    Time frame: 12, 52 weeks, yearly thereafter up to 5 years

    Absolute change from baseline in lung magnetic resonance imaging (MRI) score (Heidelberg MRI score ranging from 0 to 72 with higher values associated with worsening of the outcome; Eichinger et al. Eur J Radiol 2012)

  6. Lung computer tomography

    Time frame: 52, 104 weeks

    Absolute change from baseline in lung computer tomography (CT) score (Brody score ranging from 0 to 40,5 with higher values associated with worsening of the outcome; Brody et al. J Thorac Imaging 2006)

  7. Paranasal sinus magnetic resonance imaging (MRI)

    Time frame: 12, 52 weeks, yearly thereafter up to 5 years

    Absolute change from baseline in paranasal sinus magnetic resonance imaging (MRI) score (Sinunasal MRI score ranging from 0 to 68 with higher values associated with worsening of the outcome; Sommerburg et al. Ann Am Thorac Soc 2020)

  8. Fecal elastase

    Time frame: 12, 52 weeks, yearly thereafter up to 5 years

    Absolute change from baseline in fecal elastase-1 (FE-1) levels

  9. Weight

    Time frame: quaterly in the first year, yearly thereafter up to 5 years

    Absolute change from baseline in weight

  10. Airway Microbiome

    Time frame: 4, 12, 52 weeks, yearly thereafter up to 5 years

    Absolute change in shannon index representing the alpha-diversity in sputum samples

  11. Sputum Elasticity

    Time frame: 4, 12, 52 weeks, yearly thereafter up to 5 years

    Absolute change in the elastic modulus (G') in sputum samples measured with a rheometer

  12. Sputum Viscocity

    Time frame: 4, 12, 52 weeks, yearly thereafter up to 5 years

    Absolute change in the viscous modulus (G'') in sputum samples measured with a rheometer

  13. Cystic Fibrosis Questionnaire-Revised (CFQ-R)

    Time frame: quarterly in the first year, yearly thereafter up to 5 years

    The Cystic Fibrosis Questionnaire-Revised is a disease-specific health-related quality of life instrument for individuals with cystic fibrosis. Scores are standardized on a 0-100 scale. Minimum: 0; Maximum: 100. Higher scores indicate better health-related quality of life. Absolute change from baseline is calculated as follow-up score minus baseline score.

  14. Patient Health Questionnaire-9 (PHQ-9)

    Time frame: quarterly in the first year, yearly thereafter up to 5 years

    The Patient Health Questionnaire-9 is a 9-item self-report measure assessing depressive symptom severity over the past two weeks. Total score range: 0-27. Minimum: 0; Maximum: 27. Higher scores indicate more severe depressive symptoms. Absolute change from baseline is calculated as follow-up score minus baseline score.

  15. Generalized Anxiety Disorder-7 (GAD-7)

    Time frame: quarterly in the first year, yearly thereafter up to 5 years

    The Generalized Anxiety Disorder-7 is a 7-item self-report measure assessing anxiety symptom severity over the past two weeks. Total score range: 0-21. Minimum: 0; Maximum: 21. Higher scores indicate more severe anxiety symptoms. Absolute change from baseline is calculated as follow-up score minus baseline score.

  16. Child Behavior Checklist for Ages 1½-5 (CBCL/1½-5)

    Time frame: quarterly in the first year, yearly thereafter up to 5 years

    The Child Behavior Checklist for Ages 1½-5 is a parent-reported measure assessing emotional and behavioral problems in children aged 18 months to 5 years. The Total Problems raw score ranges from 0-198. Minimum: 0; Maximum: 198. Higher scores indicate more emotional and behavioral problems. Absolute change from baseline is calculated as follow-up score minus baseline score.

  17. Child Behavior Checklist for Ages 6-18 (CBCL/6-18)

    Time frame: quarterly in the first year, yearly thereafter up to 5 years

    The Child Behavior Checklist for Ages 6-18 is a parent-reported measure of emotional and behavioral problems. Raw total problem scores range from 0-226. Minimum: 0; Maximum: 226. Higher scores indicate more behavioral and emotional problems. Absolute change from baseline is calculated as follow-up score minus baseline score.

  18. Youth Self-Report for Ages 11-18 (YSR/11-18)

    Time frame: quarterly in the first year, yearly thereafter up to 5 years

    The Youth Self-Report for Ages 11-18 is a self-report measure of emotional and behavioral problems, corresponding to the Child Behavior Checklist. Raw total problem scores range from 0-224. Minimum: 0; Maximum: 224. Higher scores indicate more behavioral and emotional problems. Absolute change from baseline is calculated as follow-up score minus baseline score.

  19. Strengths and Difficulties Questionnaire (SDQ)

    Time frame: quarterly in the first year, yearly thereafter up to 5 years

    The Strengths and Difficulties Questionnaire is a behavioral screening questionnaire. The Total Difficulties Score ranges from 0-40. Minimum: 0; Maximum: 40. Higher scores indicate more emotional and behavioral difficulties. Absolute change from baseline is calculated as follow-up score minus baseline score.

  20. 22-Item Sino-Nasal Outcome Test (SNOT-22)

    Time frame: quarterly in the first year, yearly thereafter up to 5 years

    The 22-Item Sino-Nasal Outcome Test assesses symptom severity and health-related quality of life in sinonasal disease. The total score ranges from 0-110. Minimum: 0; Maximum: 110. Higher scores indicate more severe symptoms and poorer quality of life. Absolute change from baseline is calculated as follow-up score minus baseline score.

Study contacts

Contact information is provided by the study sponsor or research team.

Simon Y Graeber, MD

CONTACT

[email protected]

+4930 450 566 587

Sponsors and collaborators

Lead sponsor

Charite University, Berlin, Germany

Other

Collaborators

  • Hannover Medical School
  • Heidelberg University
  • University of Giessen
  • University of Luebeck

Registry information

Official study title

CFTR Biomarker Studie Bei Patient*Innen Mit Mukoviszidose Und CFTR-Modulatortherapie

Acronym: Modulate-CF

Important dates

Study start
2018
Primary completion
2027
Study completion
2027
First posted
Feb 1, 2021
Registry last updated
Feb 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.